Tarceva (Erlotinib)

Lung oncology accounts for 12% of all malignant neoplasms in the world being the main cause of oncology lethality deaths. The annual incidence of the disease in Europe is 52.5 / 100,000 and the annual mortality rate is 48.7 / 100,000 total mortality.

Read More

Revlimid (Lenalidomide)

Antineoplastic drug, immunomodulator Relvimid (Lenalidomid) has both immunomodulatory, and antiangiogenic properties. It inhibits secretion of pro-inflammatory cytokine, including FNO, interleukin-1 (IL-1), IL-6 and IL-12, from liposaccharide (LPS) – the stimulated peripheral mononuclear blood cells (PMBC).

Read More